Trial · NCT02247245
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
NCT02247245, Not applicable, Completed, University of Leeds; results first posted 2020-01-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. Trials, record NCT02247245. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02247245
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
- NCT number
- NCT02247245
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, actual
- Lead sponsor
- University of Leeds
- Conditions
- Chronic Heart Failure, Atrial Fibrillation, Arrhythmia, Sinus
- Interventions
- Ivabradine, Atrial fibrillation, Placebo
- First posted
- 2014-09-23
- Last updated
- 2020-01-02
- Results first posted
- 2020-01-02
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximal Oxygen Consumption (Peak VO2) | Each test lasts up to 20 minutes | Cardiopulmonary exercise testing performance - measuring peak oxygen uptake during a treadmill CPEX test. Subjects were exercised using the Bruce protocol, modified by the addition of a "stage 0" at onset consisting of 3 min of exercise at 1.61 km·h-1 (1 mile·h-1) with a 5% gradient. Expired air was collected and metabolic gas exchange analysis performed in order to measure the maximal oxygen consumption (peak VO2) (Sensormedics, Yorba Linda, California). The CPX equipment was recalibrated before every exercise test. All test subjects were encouraged to exercise to exhaustion before starting the test, and no further motivation or instructions were given. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximal Oxygen Consumption (Peak VO2) | Each test lasts up to 20 minutes | ml/kg/min | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximal Oxygen Consumption (Peak VO2) | Placebo | 16 | Standard Error 3 | ml/kg/min | |
| Maximal Oxygen Consumption (Peak VO2) | Ivabradine | 17 | Standard Error 3 | ml/kg/min | |
| Maximal Oxygen Consumption (Peak VO2) | Atrial Fibrillation: Low Base Rate (+no Rate Adaptive Pacing) | 15.3 | Standard Error 1.9 | ml/kg/min | |
| Maximal Oxygen Consumption (Peak VO2) | Atrial Fibrn: Standard Base Rate (+Rate Adaptive Pacing) | 14.2 | Standard Error 2.1 | ml/kg/min |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo First | 13 | |
| Overall Study | STARTED | Ivabradine First | 13 | |
| Overall Study | STARTED | Atrial Fibrillation (Low Rate) | 7 | |
| Overall Study | STARTED | Atrial Fibrillation (Standard Rate) | 7 | |
| Overall Study | COMPLETED | Placebo First | 13 | |
| Overall Study | COMPLETED | Ivabradine First | 13 | |
| Overall Study | COMPLETED | Atrial Fibrillation (Low Rate) | 7 | |
| Overall Study | COMPLETED | Atrial Fibrillation (Standard Rate) | 7 | |
| Overall Study | NOT COMPLETED | Placebo First | 0 | |
| Overall Study | NOT COMPLETED | Ivabradine First | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 13 |
| Total, all-cause mortality | Ivabradine | 0 | 13 |
| Total, all-cause mortality | Atrial Fibrillation (Low Rate) | 0 | 7 |
| Total, all-cause mortality | Atrial Fibrilaltion (Standard Rate) | 0 | 7 |
| Total, other adverse events | Placebo | 0 | 13 |
| Total, other adverse events | Ivabradine | 0 | 13 |
| Total, other adverse events | Atrial Fibrillation (Low Rate) | 0 | 7 |
| Total, other adverse events | Atrial Fibrilaltion (Standard Rate) | 0 | 7 |
| Total, serious adverse events | Placebo | 0 | 13 |
| Total, serious adverse events | Ivabradine | 0 | 13 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27102504 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02247245
GET https://conductscience.org/api/trials/v1/NCT02247245/registered